Company profile KROS

Keros Therapeutics Inc
keros therapeutics, inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. the company's lead protein therapeutic product candidate is ker-050, which is being developed for the treatment of low blood ce...ll counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or mds, and in patients with myelofibrosis. it is also developing small molecule product candidate ker-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or fop, and is currently in a phase 1 clinical trial; and ker-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or pah. the company was founded i Show More
Quarter analysis & expected interest

There is not enough data for Keros Therapeutics login to provide analysis

Correlation between past revenue and Keros Therapeutics login search interest

There is not enough data for Keros Therapeutics login to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Keros Therapeutics login to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Keros Therapeutics stock news to provide analysis

Correlation between past revenue and Keros Therapeutics stock news search interest

There is not enough data for Keros Therapeutics stock news to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Keros Therapeutics stock news to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for KER-050 clinical trials to provide analysis

Correlation between past revenue and KER-050 clinical trials search interest

There is not enough data for KER-050 clinical trials to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for KER-050 clinical trials to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for KER-047 Phase II trials to provide analysis

Correlation between past revenue and KER-047 Phase II trials search interest

There is not enough data for KER-047 Phase II trials to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for KER-047 Phase II trials to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for KER-012 pulmonary arterial hypertension to provide analysis

Correlation between past revenue and KER-012 pulmonary arterial hypertension search interest

There is not enough data for KER-012 pulmonary arterial hypertension to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for KER-012 pulmonary arterial hypertension to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Keros Therapeutics address to provide analysis

Correlation between past revenue and Keros Therapeutics address search interest

There is not enough data for Keros Therapeutics address to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Keros Therapeutics address to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Keros Therapeutics executives to provide analysis

Correlation between past revenue and Keros Therapeutics executives search interest

There is not enough data for Keros Therapeutics executives to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Keros Therapeutics executives to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Keros Therapeutics contact to provide analysis

Correlation between past revenue and Keros Therapeutics contact search interest

There is not enough data for Keros Therapeutics contact to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Keros Therapeutics contact to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for KROS
Earnings date: 2024-03-01 After close
Company name: Keros Therapeutics Inc
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-05-14T12:00:00Z

GlobeNewswire
Keros Therapeutics Reports Recent First Quarter 2026 Financial Results

2026-03-09T12:00:00Z

GlobeNewswire
Keros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS

2026-03-09T12:00:00Z

GlobeNewswire
Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference

2026-03-05T16:36:56Z

Analyst Upgrades
Wells Fargo Maintains Overweight on Keros Therapeutics, Lowers Price Target to $20

2026-03-04T21:01:00Z

GlobeNewswire
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results

2026-02-26T21:01:00Z

GlobeNewswire
Keros Therapeutics Appoints Charles Newton to its Board of Directors

2026-02-18T21:01:00Z

GlobeNewswire
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

2025-11-28T17:08:06Z

Analyst Upgrades
B of A Securities Maintains Neutral on Keros Therapeutics, Raises Price Target to $19

2025-11-20T21:01:00Z

GlobeNewswire
Keros Therapeutics Announces Final Results of Tender Offer

2025-11-19T11:00:00Z

GlobeNewswire
Keros Therapeutics Announces Preliminary Results of Tender Offer

2025-11-12T16:30:46Z

Analyst Upgrades
Oppenheimer Reiterates Outperform on Keros Therapeutics, Raises Price Target to $27

2025-11-11T14:32:49Z

Analyst Upgrades
Wells Fargo Maintains Overweight on Keros Therapeutics, Lowers Price Target to $23

2025-11-06T13:35:19Z

Analyst Upgrades
Wedbush Maintains Neutral on Keros Therapeutics, Raises Price Target to $16

2025-11-05T21:01:00Z

GlobeNewswire
Keros Therapeutics Reports Third Quarter 2025 Financial Results

2025-10-20T06:09:05-04:00

SEC
SC TO-I Form - Tender offer statement by Issuer - Keros Therapeutics, Inc. (0001664710) (Subject)